What the evidence reports on tolerability, adverse events, and contraindications across the incretin class — including muscle-preservation and dose-management considerations. Not medical advice; always consult a licensed clinician.
A Formulation Problem That Reached the Emergency Department A patient presents with an injection-site abscess three weeks into a subcutaneous semaglutide protocol sourced from a state-licensed…
The scenario presents itself with increasing frequency in obesity medicine practice: a patient who has completed 36 weeks of tirzepatide (Mounjaro/Zepbound) titration, achieved 10 mg or 15 mg/week…
A patient presents with severe obstructive sleep apnea — apnea-hypopnea index (AHI) of 64 events per hour — and a BMI of 39 kg/m². Two CPAP trials have failed: one due to claustrophobia, one due to…
GLP-1 therapy and lean muscle mass preservation represent one of the most clinically consequential body composition questions in pharmacological weight management. A patient on semaglutide 2.4 mg…
A patient with a BMI of 38 initiates semaglutide 0.25 mg/week (Wegovy) and advances on calendar schedule at week 4 to 0.5 mg. Nausea begins on day 2 of the new dose. At week 8, the prescriber…
The Patient Who Stopped Too Soon A 47-year-old woman, 214 lbs at peak, had worked down to 171 lbs over 14 months on semaglutide 2.4 mg weekly. She felt great. Her physician agreed she could take a…
The Problem Nobody Warned Their Patients About A 54-year-old woman comes back for her 12-week semaglutide check-in. She's down 22 pounds. Her physician is thrilled. But when you pull up her DEXA…
What the evidence and FDA prescribing information report on GLP-1 side effects, how GI symptoms are managed, and long-term safety data. Not medical advice.